DonaldJensenMDFACP, FAASLD

PubMed

• The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents.
  Donald M Jensen, Allison Rzepczynski, Emily E Jensen, Nancy Reau
  Hepatology. 2022-09-01
• A Case of Rapid Decline in Alcohol-Associated Liver Disease.
  Aashesh N Verma, Donald M. Jensen
  Clinical Liver Disease. 2021-02-01
• 18 citations
  Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
  Thomas G. Cotter, Donald M. Jensen
  Drug Design, Development and Therapy. 2019-07-29

Journal Articles

• Novel Educational Interventions in Residency Increase Knowledge of Chronic Liver Disease and Career Interest in Hepatology  
  Mikolajczyk AE, Farnan JM, McConville JF, Jensen DM, Reddy KG, Te HS, Reau N, Aronsohn AI, Hepatology, 1/10/2016
• Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer  
  Kataria Y, Deaton RJ, Enk E, Jin M, Petrauskaite M, Dong L, Goldenberg JR, Cotler SJ, Jensen DM, van Breemen RB, Gann PH, BMC Gastroenterol, 1/1/2016
• Faldaprevir, pegylated interferon, and ribavirin for treatment-naive HCV genotype-1: pooled analysis of two phase 3 trials  
  Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourliere M, Hassanein T,..., Ann Hepatol, 1/1/2016
• Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis  
  Kao JH, Jensen DM, Manns MP, Jacobson I, Kumada H, Toyota J, Heo J, Yoffe B, Sievert W, Bessone F, Peng CY, Roberts SK, Lee YJ, Bhore R, Mendez P, Hughes E, Noviello S, Liver Int, 1/1/2016
• The benefit of paracentesis on hospitalized adults with cirrhosis and ascites  
  Gaetano JN, Micic D, Aronsohn A, Reddy G, Te H, Reau NS, Jensen D, J Gastroenterol Hepatol, 1/1/2016
• Generic medications for hepatitis C  
  Jensen DM, Sebhatu P, Reau NS, Liver Int, 1/1/2016
• A call to action: The need for hepatology-focused educational interventions in Internal Medicine Residency training  
  Mikolajczyk AE, Aronsohn AA, McConville JF, Jensen DM, Farnan JM, Hepatology, 1/1/2015
• Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C  
  Welch NM, Jensen DM, Liver Int, 1/1/2015
• Clinical impact of treatment timing for chronic hepatitis C infection: a decision model  
  Pho MT, Jensen DM, Meltzer DO, Kim AY, Linas BP, J Viral Hepat, 1/1/2015
• Daclatasvir and Asunaprevir Plus Peginterferon Alfa and Ribavirin in HCV Genotype 1 or 4 Non-responders  
  Jensen DM, et al, J Hepatol, 1/1/2015
• Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?  
  Sengupta S, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, Te H, Dig Dis Sci, 1/1/2015
• Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus  
  AASLD/IDSA HCV Guidance Panel, Hepatology, 1/1/2015
• Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection  
  Michael G. Berg, Deanna Lee, Kelly Coller, Matthew Frankel, Andrew Aronsohn, Kevin Cheng, Kenn Forberg, Marilee Marcinkus, Samia N. Naccache, George Dawson, Catherine ..., PLoS Pathog, 1/1/2015
• Randomised study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partil or null responses to peginterferon/ribavirin  
  Feld J, Jacobson I, Jensen DM, Foster G, Pol s, Tam E, Jablkowski M, Berak H, Vierling J, Yoshida E, Perez-Gomez H, Le Pogam S, Najera I, Eng S, Yin Lim C, Shulman N a..., J Hepatol, 1/16/2014
• Faster than a speeding bullet  
  Jensen DM and Nathanson M, Hepatology, 1/4/2014
• Preparing for the uncertain yet inevitable off-label combinations of antiviral agents in hepatitis C virus  
  Aronsohn A, Reau N and Jensen DM, Hepatology, 1/1/2014
• Advances in combination regimens in the management of HCV infection  
  Jensen DM, Gastroenterol Hepatol (NY), 1/1/2014
• A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy  
  Cassandra D.L. Fritz, Corlan Adebajo, Andrew Aronsohn, Donald M. Jensen, ACG Case Rep J, 1/1/2014
• Retreatment of HCV with ABT450/r-ombitasvir and dasabuvir with ribavirin  
  Zeuzem S, Jacobson I, Baykal T, Marinho R, Poordad F, Bouliere M, Sulkowski M, Wedemeyer H, Tam E, Desmond P, Jensen D, DiBisceglie A, Varunok P, Hassanein T, Xiong J,..., N Engl J Med, 1/1/2014
• Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease  
  Desai A, Satoskar R, Appannagari A, Reddy KG, Te HS, Reau NS, Meltzer DO and Jensen DM, J Clin Gastroenterol, 1/1/2014
• Human immunodeficiency virus and coinfection with hepatitis B and C  
  Petty LA, Steinbeck JL, Pursell K and Jensen DM, Infect Dis Clin North Am, 1/1/2014
• Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus  
  Aronsohn A and Jensen DM, Hepatology, 1/1/2014
• Interferon-combination strategies for the treatment of chronic hepatitis C  
  Aronsohn A and Jensen D, Semin Liver Dis, 1/1/2014
• Advances in combination regimens in the management of HCV infection  
  Jensen DM, Gastroenterol Hepatol (N.Y.), 1/1/2014
• Sticker shock and the price of new therapies for hepatitis C: Is it worth it?  
  Reau NS and Jensen DM, Hepatology, 1/1/2014
• Join now to see all

Books/Book Chapters

• Hepatocellular Carcinoma: A Practical Approach 
  Chapter: Tumor Markers and Molecular Biology 
  Page 62 - 81Mohanty S and Jensen DMEditors: Al Knawy B, Reddy R, Bolondi L.Informa Healthcare2009
• Clinics in Liver Disease 
  Chapter: Vanishing Bile Duct Syndrome 
  Page 203 - 217Reau NS, Jensen DM2008
• Clinics in Liver Disease 
  Chapter: Serum enzymes tests in the evaluation of cholestasis. 
  Sotil EU, Jensen DM2004
• Clinics in Liver Dis 
  Chapter: Hepatitis C and HIV coinfection. 
  Page 1045 - 1061otler SJ and Jensen DM2001
• Chronic Viral Hepatitis 
  Chapter: Hepatitis B and Hepatitis C Coinfection 
  Angtuaco T and Jensen DMEditors: Raymond Koff and George Wu.2001
• Medical Management of Liver Disease 
  Chapter: Management of Chronic Hepatitis C 
  Page 99 - 114Cotler S and Jensen DMEditors: Edward Krawitt.Marcel Dekker, Inc.1999
• Quick Reference to Internal Medicine: Outline Format 
  Chapter: Primary Sclerosing Cholangitis. 
  Page 829 - 830Jensen DMEditors: Bone, RC and Rosen, RL.Igaku-Shoin Ltd. Publishing, New York1994
• Quick Reference to Internal Medicine: Outline Format 
  Chapter: Acute Liver Failure. 
  Page 346 - 346Jensen DMEditors: Bone, RC and Rosen, RL.Igaku-Shoin Ltd. Publishing, New York1994
• Quick Reference to Internal Medicine: Outline Format 
  Chapter: Granulomatous Diseases. 
  Page 847 - 849Jensen DMEditors: Bone, RC and Rosen, RL.Igaku-Shoin Ltd. Publishing, New York1994
• Quick Reference to Internal Medicine: Outline Format 
  Chapter: Hepatic Transplantation. 
  Page 845 - 846Jensen DMEditors: Bone, RC and Rosen, RL.Igaku-Shoin Ltd. Publishing, New York1994
• Quick Reference to Internal Medicine: Outline Format 
  Chapter: Hepatic Encephalopathy. 
  Page 837 - 838Jensen DMEditors: Bone, RC and Rosen, RL.Igaku-Shoin Ltd. Publishing, New York1994
• Quick Reference to Internal Medicine: Outline Format 
  Chapter: Chronic Hepatitis. 
  Page 825 - 826Jensen DMEditors: Bone, RC and Rosen, RL.Igaku-Shoin Ltd. Publishing, New York1994
• Quick Reference to Internal Medicine: Outline Format 
  Chapter: Acute Pancreatitis. 
  Page 805 - 808Jensen DMEditors: Bone, RC and Rosen, RL.Igaku-Shoin Ltd. Publishing, New York1994
• Quick Reference to Internal Medicine: Outline Format 
  Chapter: Liver Biopsy. 
  Page 727 - 728Jensen DMEditors: Bone, RC and Rosen, RL.Igaku-Shoin Ltd. Publishing, New York1994
• Quick Reference to Internal Medicine: Outline Format 
  Chapter: Alcoholic Liver Disease. 
  Page 821 - 824Jensen DM and Sabesin SEditors: Bone, RC and Rosen, RL.Igaku-Shoin Ltd. Publishing, New York1994
• Quick Reference to Internal Medicine: Outline Format 
  Chapter: Viral Hepatitis. 
  Page 819 - 820Jensen DMEditors: Bone, RC and Rosen, RL.Igaku-Shoin Ltd. Publishing, New York1994
• Quick Reference to Internal Medicine: Outline Format 
  Chapter: Chronic Pancreatitis. 
  Page 809 - 810Jensen DMEditors: Bone, RC and Rosen, RL.Igaku-Shoin Ltd. Publishing, New York1994
• Rush University Review of Surgery 
  Chapter: The Liver 
  Page 294 - 302Jensen DMEditors: S.G. Economou, D. Deziel, T. Witt, S. Bines, T, Saclarides, E. Staren and T. Velasco.W.B. Saunders Co.,, Philadelphia1993
• Current Therapy in Critical Care Medicine 
  Chapter: Acute pancreatitis. 
  Page 275 - 278Jensen, DM and Sabesin, SMEditors: J. Parillo.B.C. Decker Inc., Philadelphia1991
• Problems in General Surgery 
  Chapter: Gallstone lithotripsy. 
  Page 390 - 399Deziel, DJ and Jensen DMEditors: S.G. Economou.J.B. Lippincott Co., Philadelphia1989
• Medical Clinics of North America 
  Chapter: Portal-systemic encephalopathy and hepatic coma. 
  Page 1081 - 1092Jensen, DM1986
• Immune Reactions in Liver Disease 
  Chapter: Comparison of anti-LSP responses in predictable and idiosyncratic drug reactions. 
  Jensen, DMEditors: ALWF Eddleston, JCP Weber, R. Williams.Pitman Medical Publish Co., Ltd., Turnbridge Wells, England1979
• Join now to see all

Abstracts/Posters

• Retinoid/Carotenoid Depletion in Hepatitis C: Fibrosis Stage in Relation to Serum Biomarkers for Antioxidant Status, Insulin Resistance & Oxidative Stress.
  Chung B, Rueter EE, Cotler S, Jensen DM, Guzman G, van Breemen R, Gann P, USCAP (United States and Canadian Academy of Pathology), 1/1/2014
• High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT ¼ patients treated with RG7128 plus PEGIFN alfa-2a (...
  Jensen DM, et al, Hepatology, AASLD (American Association for the Study of Liver Diseases), 1/1/2010
• Interferon is underutilized in hepatitis B (HBV) patients most likely to have a favorable outcome.
  eau N, Choi C, Te H, Mohanty S, Aronsohn A, Reddy G, Jensen DM, Hepatology, AASLD (American Association for the Study of Liver Diseases), 1/1/2010
• Liver biopsy changes the management of HBV in 48% of treatment naive patients.
  Choi C, Reau N, Te H, Mohanty S, Reddy G, Jensen DM, Hepatology, AASLD (American Association for the Study of Liver Diseases), 1/1/2010
• Physician preference drives choice of oral hepatitis B therapy.
  Reau N, Choi C, Te H, Mohanty S, Aronsohn A, Reddy G, Jensen DM, Hepatology, AASLD (American Association for the Study of Liver Diseases), 1/1/2010
• Differential association of a chromosome 19 single nucleotide polymorphism (SNP: rs12979860) to outcome (early virologic response/sustained virologic response EVR/SVR)...
  Asselah T, Essioux L, Marcellin P, Fried M, Jensen DM, Germer S, Benayed R, Chu T, Tietz A, Cchin D, Shulman N, Thommes J, Laughlin M, Lopatin U, Hepatology, AASLD (American Association for the Study of Liver Diseases), 1/1/2010
• Optimizing hepatitis C treatment in practice: an assessment of physician stage-of-change in practice improvement.
  Brown J, Johnson S, Jensen DM, Fried M, Cummins CO, Paiva A, Carney B, Hepatology, AASLD (American Association for the Study of Liver Diseases), 1/1/2010
• Refractory Spontaneous Bacterial Peritonitis: A Retrospective Study of the University of Chicago Experience.
  Jensen DM, EASL (European Association for the Study of the Liver), 1/1/2009
• Are the attitudes and practices of hepatologists and transplant surgeons regarding living donor transplantation in alcoholics justified?
  Aronsohn A, Thistlethwaite R, Jensen DM, Ross L, Digestive Disease Week, 1/1/2008
• Clinical and Liver Histological Differences in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) with and without Diabetes Mellitus (DM).
  Lee, Ye-Jin; Jensen, Donald M.; Te, Helen; Reau, Nancy; Reddy, Kapuluru G.; Satoskar, Rohit S.; Mishra, Poonam; Hart, John; Mohanty, Smruti R, Digestive Disease Week, 1/1/2008
• HCV RNA Status at Week 12 of Treatment with Peginterferon alfa-2a (PEGASYS®)/Ribavirin (COPEGUS®) Predicts SVR in Patients with Prior Non-Response to Pegylated Interfe...
  Marcellin P1, Freilich B, Andreone P, DiBisceglie A, Eduardo Brandao C, Reddy KR, Craxi A, Olveira A, Teuber G, Messinger D, Hooper G, Popescu M, Jensen DM, EASL (European Association for the Study of the Liver), 1/1/2008
• Easy to Assess On-treatment Parameters Correlate with Degree of Virological Response after 12 Weeks of Treatment: Results from the REPEAT Study.
  Jensen DM, Freilich B, Andreone P, DiBisceglie A, Eduardo Brandao C, Reddy KR, Craxi A, Olveira A, Teuber G, Messinger D, Hooper G, Popescu M, Tietz A,Marcellin P, EASL (European Association for the Study of the Liver), 1/1/2008
• Clinical and liver histological differences in patients with nonalcoholic fatty liver disease (NAFLD) with and without diabetes mellitus.
  Lee y-L, Jensen DM, Te H, Reau N, Reddy KG, Satoskar R, Mishra P, Hart J, Mohanty S, Gastroenterology, 1/1/2008
• Type of response to prior pegylated interferon alfa-2b(12KD)/RBV predicts subsequent response to retreatment with peginterferon alfa-2a(40KD)/RBV.
  Marcellin P, Freilich B, Andreone P, DiBeglie A, Brandao-Mello C, Reddy K, Craxi A, Olveiro A, Teuber G, Messinger D, Hooper G, Popescu M, Jensen DM, Gastroenterology, 1/1/2008
• HCV-RNA status at week 12 of treatment with peginterferon alfa-2a/RBV predicts SVR in patients with prior nonresponse to pegylated interferon alfa-2b/RBV: Results from...
  Marcellin P, Freilich B, Andreone P, DiBeglie A, Brandao-Mello C, Reddy K, Craxi A, Olveiro A, Teuber G, Messinger D, Hooper G, Popescu M, Jensen DM, Gastroenterology, 1/1/2008
• Easy to assess on-treatment parameters correlate with degree of virological response after 12 weeks of treatment.
  Jensen DM, Freilich B, Andreone P, DiBeglie A, Brandao-Mello C, Reddy K, Craxi A, Olveiro A, Teuber G, Messinger D, Hooper G, Popescu M, Marcellin P, Gastroenterology, 1/1/2008
• Is there justification for the attitudes and practices of hepatologists and transplant surgeons regarding transplantation in patients with alcoholic liver disease.
  Aronsohn A, Thistlewaite R, Jensen DM, Ross L, Gastroenterology, 1/1/2008
• Refined prediction of week 12 response and SVR based on the virological response at week 4 in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASY...
  Jensen DM, AASLD (American Association for the Study of Liver Diseases), 1/1/2008
• A 72-week treatment duration with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) has a favorable risk:benefit ratio in non-responders to pegylated int...
  Jensen DM, AASLD (American Association for the Study of Liver Diseases), 1/1/2008
• Evaluation of Early Null-response (eNR) as a Predictor of Nonresponse to PEG RBV in Patients with HCV.
  Jensen DM, AASLD (American Association for the Study of Liver Diseases), 1/1/2008
• Discordance between serum tacrolimus and immunosuppresion levels in orthotopic liver transplant (OLT) recipients.
  Jensen DM, AASLD (American Association for the Study of Liver Diseases), 1/1/2008
• Candidacy for hepatitis C clinical trials at a tertiary referral Center.
  Reddy, KG. Reau N, Te H., Mohanty S, Satoskar R, DeVoss A, Wherity K, Jensen DM, Hepatology, 1/1/2007
• Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 pa...
  Marcellin P; Jensen D; Hadziyannis S; Ferenci P, Hepatology, 1/1/2007
• A Nationwide Survey of Attitudes Toward Liver Transplantation in Alcoholic Liver Disease.
  Satoskar R; Aronsohn A; Te HS; Mohanty SR; Reddy KG; Reau N; Jensen DM, Hepatology, 1/1/2007
• Combined liver-heart transplantation in the United States.
  Te HS, Reddy, KG. Reau N, Mohanty S, Satoskar R, Jensen DM, Hepatology, 1/1/2007
• Join now to see all

Lectures

• The Financial Aspects of a Community Hepatologist. 
  1/11/2016
• Are Hepatitis C Medications Too Expensive? 
  Vienna - 1/22/2015
• Updated results of TARGET and TRIO studies. Focus on both compensated and decompensated cirrhosis with or without failure to first generation Pis. 
  Baveno, Italy - 1/17/2015
• How will high-priced new agents translate to disease eradication? 
  Australia - 1/10/2015
• Results in clinical trials are mirrored in clinical practice, even in cirrhotic patients. 
  Lisbon, Portugal - 1/1/2015
• DAA and interferon-based therapies. 
  Paris, France - 1/1/2015
• Updates on Hepatitis C and Hepatitis B 
  Ulanbatoor, Mongolia - 1/1/2014
• Update on Hepatitis C 
  1/1/2014
• Off Label Combinations of Newly Approved HCV Oral Therapies 
  HI - 1/1/2013
• Future Therapies of HCV 
  Baveno, Italy - 1/1/2013
• Future Interferon-free Therapies for Hepatitis C 
  Eilat, Israel - 1/1/2013
• Debate: The Future Will be Interferon-free HCV Therapy 
  Prague, Czech Republic - 1/1/2012
• IL28B: Ten Years Too Late 
  Paris, France - 1/1/2012
• Join now to see all

Other

• Current Developments in the Treatment of Hepatitis B and C. 
  Reau NS, Jensen DM, US Infectious Diseases
  1/1/2007
• Ductopenia and Vanishing Bile Duct Syndromes. 
  Reau N and Jensen D, UpToDate
  1/1/2007
• Infectious complications following liver transplantation. 
  Patil R and Jensen DM, UpToDate, vol 5.3, CD-ROM educational software
  1/1/1999
• Selection of Patients for Liver Transplantation. 
  Rowell D and Jensen DM, UpToDate v5.2, CD-ROM educational software
  1/1/1998
• Treatment of Acute Rejection in Liver Transplant Recipients. 
  Cotler S and Jensen DM, UpToDate v5.2, CD-ROM educational software
  1/1/1998
• Diagnosis of acute cellular rejection in liver transplant recipients. 
  Kaur S and Jensen DM, UpToDate v5.2, CD-ROM educational software
  1/1/1998
• Long-term complications of liver transplantation. 
  Cotler S and Jensen D, UpToDate v5.2, CD-ROM educational software
  1/1/1998
• The significance of normal ALT levels in patients with viral hepatitis. 
  Rowell D and Jensen DM, Viral Hepatitis Reviews
  1/1/1997
• Hepatic ductopenia and vanishing bile duct syndrome 
  Jensen DM, Reau N
  http://www.uptodate.com/contents/hepatic-ductopenia-and-vanishing-bile-duct-syndrome
  UpToDate, Wolters Kluwer Health - 2012-10-01
• Join now to see all